http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2311012-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cf7f3f36d20185ce15a2d1f04d5fdc1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2001-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_470954e4e91413e19a6a94dc384a4447 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29c841e23487588f6b669c337958bb6d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f7c5cad7f510acac6db35fd98ec120 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99195b037c22551e01c1898c95384ed0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb2421e2cdb56d4b645bb605ae90875 |
| publicationDate | 2009-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2311012-T3 |
| titleOfInvention | DOPAMINE D3 RECEIVER LINKS FOR THE ADDICTION TREATMENT. |
| abstract | Use of the compounds, which are chosen from 2 - [(3- {4- [2-tert-butyl-6- (trifluoromethyl) -4-pyrimidinyl] -1-piperazinyl} propyl) -sulfanyl] -4- pyrimidinol, 5 - ({3- [4- (3,5-dichlorophenyl) -1-piperazinyl] propyl} sulfanyl) -1,3,4-thiadiazol-2-amine, 5 - [(2-methyl- 3- (4- [3- (trifluoromethyl) phenyl] -1-piperazinyl) propyl) sulfanyl] -1,3,4-thiadiazol-2-amine, 2 - [{3- (4- [3- (trifluoromethyl) ) phenyl] -1-piperazinyl} propyl) sulfanyl] -4-pyrimidinol, 5- (6- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl) hexyl) -1,3,4-thiadiazole- 2-amine, 1 - {(2E) -4 - [(4-hydroxy-2-pyrimidinyl) sulfanyl] -2-butenyl} -4- [3- (trifluoromethyl) phenyl] piperazindiium, 4-methyl dichloride -5 - [(3- (4- [3- (trifluoromethyl) phenyl] -1-piperazinyl) propyl) sulfanyl] -4H-1,2,4-triazol-3-amine, 2 - ([3- ( 4- [3- (trifluoromethyl) phenyl] -3,6-dihydro-1 (2H) -pyridinyl) propyl] sulfanyl) -4-pyrimidinol, 2 - ({3- [4- (3-isopropylphenyl) -1 -piperazinyl] propyl} sulfanyl) -4-pyrimidinol, 5 - [(3- {4- [6- (trifluoromethyl) -2-pyridinyl] -1-piperazinyl} propyl) sulfanyl} -1,3,4-thiadiazole -2-ami na, 5 - [((2E) -4- (4- [6- (trifluoromethyl) 2-pyridinyl] -1-piperazinyl) -2-butenyl) sulfanyl] -1,3,4-thiadiazol-2-amine , 5 - ({3- [4- (3,5-diterc.-butylphenyl) 1-piperazinyl] propyl} sulfanyl) -4-methyl-4H-1,2,4-triazol-3-amine, - ({7- [4- (3-Isopropylphenyl) -1-piperazinyl] heptyl} sulfanyl) -1,3,4-thiadiazol-2-amine, 4-ethyl-5 - [(3- (4- [ 3- (trifluoromethyl) phenyl] -1-piperazinyl) propyl) sulfanyl] -4H-1,2,4-triazol-3-amine, 3- (4- {8 - [(5-amino-1,3, 4-thiadiazol-2-yl) sulfanyl] octyl) -1-piperazinyl) -benzonitrile, 5 - [(3- (4- [6-methyl-2- (1H-pyrrol-1-yl) -4-pyrimidinyl) ] -1-piperazinyl} propyl) -sulfanyl] -1,3,4-thiadiazol-2-amine, 4-methyl-5 - [(3- {4- [6-methyl-2- (1H-pyrrole- 1-yl) -4-pyrimidinyl] -1-piperazinyl} -propyl) sulfanyl] -4H-1,2,4-triazol-3- amine, the 5 - [{(2E) -4- (4- [2 -terc.-butyl-6- (trifluoromethyl) -4-pyrimidinyl] -1-piperazinyl) -2-methyl-2-butenyl} sulfanyl] -4-methyl-4H-1,2,4-triazol-3-amine , 1- [3- (difluoromethyl) phenyl) -4- (3 - ([4-methyl-5- (methylammonium) -4H-1,2,4-triazol-3-yl] sulfanyl) propyl) dichloride piperazin- 4-io and the 5 - ({3- [4- (2,6-diterc.-butyl-4-pyrimidinyl) -1-piperazinyl] propyl} sulfanyl) -1,3,4-thiadiazol-2-amine, or its salts with physiologically compatible acids, to obtain a drug for the treatment of addiction. |
| priorityDate | 2000-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 130.